Skip to main content

Table 4 Association between CYP2C19*2, *3, PON1 Q192R and clopidogrel resistance

From: The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

GenotypeCrude OR(95%CL)P valueAdjusted OR
(95%CL)
P value
CYP2C19*2(GG)1 1 
CYP2C19*2(GA)2.81(1.12–6.59)0.0182.99(1.11–8.03)0.03
CYP2C19*2(AA)12.47(3.77–41.22)< 0.0018.62(2.29–32.46)0.001
CYP2C19*3(GG)1 1 
CYP2C19*3(GA)5.31(1.96–14.41)< 0.0013.64(0.98–13.56)0.054
1*/1*1 1 
1*/2*4.41(1.35–14.41)0.146.65(1.77–25.04)0.005
1*/3*10.89(2.36–50.30)0.00222.74(3.11–166.27)0.002
2*/2*27.96(6.77–115.52)< 0.00148.49(8.16–287.97)< 0.001
2*/3*106.75(10.42–1093.57)< 0.001241.32(14.59–3991.37)< 0.001
PON1(Q192R)QQ(AA)1 1 
PON1(Q192R)QR(AG)2.68(0.56–12.90)0.223.01(0.53–17.05)0.213
PON1(Q192R)RR(GG)5.47(1.19–25.23)0.0295.69(1.06–30.47)0.042
  1. p < 0.05: Risk is statistical significant when compared to the reference genotype